CA2227421A1 - Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ - Google Patents

Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ Download PDF

Info

Publication number
CA2227421A1
CA2227421A1 CA002227421A CA2227421A CA2227421A1 CA 2227421 A1 CA2227421 A1 CA 2227421A1 CA 002227421 A CA002227421 A CA 002227421A CA 2227421 A CA2227421 A CA 2227421A CA 2227421 A1 CA2227421 A1 CA 2227421A1
Authority
CA
Canada
Prior art keywords
cells
decrease
isopropoxyisoflavone
ipriflavone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227421A
Other languages
English (en)
Inventor
Gyorgy Varai
Attila Tar
Attila B.Kovacs
Terezia Kerepesi
Peter Aranyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2227421A1 publication Critical patent/CA2227421A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique appropriée pour diminuer le nombre de cellules CD8+ comprenant comme principe actif de la 7-isopropoxyisoflavone en mélange avec des transporteurs inertes appropriés, solides ou liquides, et, facultativement, des additifs et adjuvants thérapeutiques usuels. La composition pharmaceutique de l'invention est préparée par des méthodes connues et convient pour le traitement des sujets humains ou animaux dont l'état rend souhaitable la suppression sélective des lymphocytes CD8+.
CA002227421A 1995-07-21 1996-07-16 Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+ Abandoned CA2227421A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9502198 1995-07-21
HU9502198A HU9502198D0 (en) 1995-07-21 1995-07-21 Novel indication

Publications (1)

Publication Number Publication Date
CA2227421A1 true CA2227421A1 (fr) 1997-02-06

Family

ID=10987063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227421A Abandoned CA2227421A1 (fr) 1995-07-21 1996-07-16 Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+

Country Status (22)

Country Link
EP (1) EP0841915A1 (fr)
JP (1) JP2001503371A (fr)
KR (1) KR19990028933A (fr)
CN (1) CN1191483A (fr)
AR (1) AR002905A1 (fr)
AU (1) AU6367096A (fr)
BG (1) BG102182A (fr)
BR (1) BR9610187A (fr)
CA (1) CA2227421A1 (fr)
CZ (1) CZ2798A3 (fr)
EA (1) EA199800146A1 (fr)
EE (1) EE9800020A (fr)
HR (1) HRP960345A2 (fr)
HU (1) HU9502198D0 (fr)
IL (1) IL122751A0 (fr)
MX (1) MX9800603A (fr)
NO (1) NO980127D0 (fr)
PL (1) PL324460A1 (fr)
SK (1) SK3298A3 (fr)
WO (1) WO1997003664A1 (fr)
YU (1) YU42796A (fr)
ZA (1) ZA966079B (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241079B (it) * 1990-03-23 1993-12-29 Chiesi Farma Spa Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
HU212932B (en) * 1993-08-02 1996-12-30 Chinoin Gyogyszer Es Vegyeszet Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition

Also Published As

Publication number Publication date
AR002905A1 (es) 1998-04-29
EE9800020A (et) 1998-08-17
SK3298A3 (en) 1998-07-08
KR19990028933A (ko) 1999-04-15
AU6367096A (en) 1997-02-18
EP0841915A1 (fr) 1998-05-20
CZ2798A3 (cs) 1998-06-17
MX9800603A (es) 1998-04-30
BG102182A (en) 1998-08-31
IL122751A0 (en) 1998-08-16
NO980127L (no) 1998-01-12
JP2001503371A (ja) 2001-03-13
HU9502198D0 (en) 1995-09-28
PL324460A1 (en) 1998-05-25
ZA966079B (en) 1998-01-19
EA199800146A1 (ru) 1998-08-27
BR9610187A (pt) 1998-07-28
YU42796A (sh) 1999-03-04
WO1997003664A1 (fr) 1997-02-06
NO980127D0 (no) 1998-01-12
HRP960345A2 (en) 1998-02-28
CN1191483A (zh) 1998-08-26
WO1997003664A8 (fr) 1999-08-05

Similar Documents

Publication Publication Date Title
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
US20050049205A1 (en) Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
Dutra et al. Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms
US10660865B2 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
Ichikawa et al. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers
WO2009102021A1 (fr) Traitement de maladie rétinienne par activation de la fonction de cellule souche issue de moelle osseuse ou de cellule progénitrice de celle-ci
JP2003510353A (ja) 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用
EP0251134A2 (fr) Compositions pour prévenir le rejet de la greffe
WO2015114315A1 (fr) Utilisation de cladribine pour traiter la neuromyélite optique
Pabst et al. Regeneration of heterotopically transplanted autologous splenic tissue
WO2004103263A2 (fr) Dopamine et ses agonistes et antagonistes permettant de traiter des maladies neurodegeneratives
AU615745B2 (en) Method of effecting immunosuppression
Hawley et al. Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas
CA2227421A1 (fr) Utilisation d'ipriflavone pour reduire le nombre de lymphocytes cd8+
Ryffel et al. Immunosuppressive effect of cyclosporin A in two lymphocyte transfer models in rats: comparison of in vivo and in vitro treatment
KR102316961B1 (ko) 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
EP0680756B1 (fr) Utilisation d'une combinaison d'antinéoplastones pour la fabrication d'un médicament pour le traitement de la neurofibromatose
KR102383866B1 (ko) 자가 면역 질병 및 당뇨병의 치료를 위한 바이러스 벡터 및 그의 제조방법 및 응용
Tomioka et al. In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648
CN110882240A (zh) 作为急性缺血性中风的治疗剂的多酚衍生物化合物6-cepn
EP4292663A2 (fr) Utilisation de cladribine pour le traitement d'une maladie neuromusculaire auto-immune
MXPA98000603A (en) Use of ipriflavona to reduce the number of cells c
Strober ‘Managing’the Immune System With Total Lymphoid Irradiation
US11944601B2 (en) Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation
JP2928608B2 (ja) インスリン依存型糖尿病予防または治療剤

Legal Events

Date Code Title Description
FZDE Discontinued